+44 20 8123 2220 [email protected]

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile https://marketpublishers.com/r/JCB7887443BEN.html Date: October 2018 Pages: 632 Price: US$ 250.00 (Single User License) ID: JCB7887443BEN

Abstracts

Summary

Johnson & Johnson (J&J) researches and develops, and manufactures and sells a range of pharmaceutical products, medical devices and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in baby care, oral care, beauty, over-the-counter (OTC) pharmaceutical, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopedic, surgery, diabetes care and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.

Business Description - A brief description of the company's operations.

Key Employees - A list of the key executives of the company.

Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors - A list of the key competitors of the company.

Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion/divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

Note: Some sections may be missing if data is unavailable for the company.

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

Contents

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 Johnson & Johnson, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 Johnson & Johnson, Medical Devices Deals, 2012 to YTD 2018 Johnson & Johnson, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 Johnson & Johnson, Pharmaceuticals & Healthcare, Deal Details Asset Purchase Janssen Pharma Acquires CERC-501 from Cerecor Acquires Rights to Rhinocort Aqua Outside the US from Astrazeneca Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir Venture Financing Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing PhaseBio Pharma Raises USD34 Million in Series D Venture Financing ApoGen Biotech Raises Additional USD4 Million in Series A Financing Magnolia Neurosciences Raises USD31 Million in Series A Venture Financing Evolve BioSystems Raises USD40 Million in Series C Financing Syndesi Therapeutics Raises USD21 Million in Series A Financing On Target Labs Raises USD40 Million in Series B Financing BeneVir Biopharm Raises USD2 Million in Venture Financing Fusion Pharma Raises Additional USD17 Million in Series A Financing XW Labs Raises USD17.5 Million in Series B Financing Rodeo Therapeutics Raises USD5.9 Million in Series A Financing E-scape Bio Raises Additional USD8 Million in Series A Financing DayTwo Secures USD12 Million in Series A Funding DayTwo Raises USD12 Million in Series A Financing Aragon Pharmaceuticals Raises USD22 Million in Series B Round of Financing Biomx Raises USD24 Million in Series A Venture Financing Pulmocide Raises USD30.4 Million in Series B Financing Fusion Pharma Raises USD19 Million in Series A Financing SuperX Raises USD11 Million in Series A Financing Caelus Health Raises USD2.7 Million in Series A Financing

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

ApoGen Biotech Raises USD7 Million in Series A Financing ReVision Optics Raises USD32 Million in Venture Financing Blackthorn Therapeutics Raises USD40 Million in Series A Financing BeneVir Biopharm Raises USD3 Million in Venture Financing V-Wave Raises USD28 Million in Venture Financing Lodo Therapeutics Raises USD17 Million in Series A Financing Aelix Therapeutics Raises USD12.7 Million in Series A Financing Petra Pharma Raises USD48 Million in Series A Financing Protekt Therapeutics Raises More Than USD2 Million in Financing Navitor Pharma Raises USD33 Million in Series B Financing First Aid Shot Therapy Raises USD24 Million in Series C Financing PrEP Biopharm Raises USD32.4 Million in Series A Financing Round Asceneuron Raises USD30.6 Million in Series A Financing Merus Raises USD46.4 Million in First Tranche of Series C Financing E-scape Bio Raises USD55 Million in Series A Financing Alligator Bioscience to Raise Funds through Venture Financing Protagonist Therapeutics Raises USD40 Million in Series C Financing PhaseBio Pharma Raises USD40 Million in Series C Venture Financing Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing BeneVir Biopharm Raises Funds through Series A Financing Tetra Discovery Raises Funds through Venture Financing XW Labs Raises USD5.5 Million in Series A Financing Inviata Raises USD6.5 Million in Venture Financing ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing Ascelegen Therapeutics Raises Funds through Venture Financing Padlock Therapeutics Raises Funds through Series A Financing Navitor Pharma Raises USD24 Million in Series A Financing Aduro BioTech Raises USD55 Million in Series C Financing Rodin Therapeutics Raises USD13 Million in Series A Venture Financing Assembly Pharma Raises Funds Through Seed Financing Alios BioPharma Raises US$41 Million In Series B Venture Financing Covagen Raises US$50.3 Million In Series B Financing Novira Therapeutics Raises US$28 Million In Series A Financing SutroVax Raises Funds Through Initial Financing Round TopiVert Raises USD28 Million in Venture Financing TopiVert Raises US$7.4 Million In Venture Financing Pulmocide Raises US$27.4 Million In Series A Financing Biocartis Raises US$40.5 Million In Series E Financing

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

Merus Raises US$42 Million In Extended Series B Financing Rodin Therapeutics Raises Funds Through Seed Financing Vedanta Biosciences Raises Funds Through Venture Financing XO1 Raises USD11 Million in Venture Financing X01 Raises US$11 Million In Series A Financing Catalyst Biosciences Secures USD5.07 Million in Venture Funding Novira Therapeutics Secures USD25 Million in Venture Funding Aquinox Pharma Raises US$18 Million In Series C Financing Biocartis Raises US$44.7 Million In Series D Financing Genocea Biosciences Raises US$30 Million In Series C Financing Aragon Pharma Raises US$50 Million In Series D Financing PhaseBio Pharma Raises Additional US$23 Million In The Third Tranche Of Series B Financing Round Celladon Raises Additional US$10 Million In Series D Financing Direct Flow Medical Secures USD0.28 Million in Venture Funding Coherex Medical Secures USD16.5 Million in Venture Funding Aragon Pharma Raises US$42 Million In Series C Financing Private Equity Johnson & Johnson Innovation - JJDC to Invest USD75 Million in Arrowhead Pharma Platinum Equity Acquires LifeScan from Johnson & Johnson for USD2.1 Billion Johnson & Johnson Innovation-JJDC Invests USD4.7 Million in TRACON Pharma Partnerships Janssen Amends Licensing Agreement with Gilead for STR Janssen Enters Into Licensing Agreement With PATH For Janssen Pharma to Enter into Research and Option Agreement with Arrowhead Pharma Janssen & Prevention, CEPI and Jenner Institute Enter into Partnership RespireRx Pharma Enters into Agreement Noramco Merck Enters into Co-Development Agreement with Xian-Janssen Pharma GenomeDx Biosciences Enters into Agreement with Janssen Pharma Noramco and SPI Pharma Enter into Agreement Bristol-Myers Squibb Enters into Partnership with Janssen Pharma Janssen Pharma to Enter into Agreement with Pharmstandard Aldeyra Therapeutics Enters into Research Agreement with Janssen Research & Development Enters into Co-Development Agreement with Theravance Biopharma Ireland Janssen Biotech Enters into Research Agreement with Koch Institute for Integrative Cancer Research

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

Johnson & Johnson Innovation and Janssen Biotech Enter into Partnership with Monash University Janssen Pharma Enters into Research Partnership with Beacon Discovery Johnson & Johnson Innovation, Johnson & Johnson Consumer Enter into Partnership with Dermala Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania Johnson & Johnson Innovation, Johnson & Johnson Consumer and Janssen Research & Development Enter into Research Partnership with Holobiome Johnson & Johnson Innovation, Janssen Research & Development Enter into Partnership with Taiwan Industrial Technology Research Institute Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma Taiho Pharma Enters into Co-Marketing Agreement with Janssen Pharma Genomic Health Enters into Research Agreement with Janssen Pharma BioMed X Enters into Agreement with Janssen Research & Development Cerveau Technologies Enters into Agreement with Janssen Pharma Janssen Research & Development Enters into Agreement with U.S. Department of Health Janssen Pharmaceutica Enters into Distribution Agreement with Mundipharma Medical Johnson & Johnson to Enter into Agreement with Institute of Microbial Technology Proteros biostructures Enters into Research Agreement with Janssen Biotech University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma Idorsia and Janssen Biotech to Enter into option Agreement Monash University Enters into Research Agreement with Janssen Biotech Phagelux Enters into Agreement with Johnson & Johnson Consumer Janssen Research & Development Enters into Agreement with Castleman Disease Collaborative Network PeptiDream Enters into Agreement with Janssen Pharma Janssen Pharma Enters into Partnership with Premier Renova Therapeutics Enters into Agreement with Janssen Pharma Mitsubishi Tanabe Pharma Expands Co-Promotion Agreement with Janssen Pharma Janssen Research & Development Enters into Research Agreement with Weizmann Institute of Science Janssen Research & Development Enters into Agreement with DayTwo and the Weizmann Institute of Science Janssen Research & Development Enters into Agreement with ChemDiv DePuy Enters into Co-Promotional Agreement with Pacira Pharma for EXPAREL

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

Enamine Expands Agreement with Karolinska Institutet Partners with Johnson & Johnson Companies Janssen Biotech Enters into Partnership with Bristol-Myers & Prevention Enters into Research and Licensing Option Agreement with Synthetic Genomics Janssen Biotech Partners with Weill Cornell Medicine to Develop Prostate Cancer Therapies Janssen Pharma Enters into Partnership with Bird Rock Bio Janssen Pharma Enters into Agreement with Medicines for Malaria Venture Amorsa Therapeutics Enters into Partnership with Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma HitGen Enters into Agreement with Janssen Biotech Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech Xycrobe Therapeutics Enters into Research Agreement with Johnson & Johnson Consumer Philogen Enters Into Collaboration Agreement With Janssen Biotech Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech Amyris Enters into Research Agreement with Janssen Biotech Janssen Research & Development Enters into Agreement with Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech DiamiR Enters into Research Agreement with Janssen Pharma Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer Janssen Biotech Enters into Agreement with HUB foundation Janssen Pharma Enters into Agreement with University of Pennsylvania Janssen Pharma Enters into Agreement with University of Wisconsin-Madison Johnson & Johnson Consumer Enters into Agreement with ProdermIQ Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC Janssen Pharma Enters into Agreement with University of California, San Diego Enterome Bioscience Enters into Research Agreement with Janssen Biotech Johnson & Johnson Consumer Enters into Agreement with BioMed X Janssen Pharma Enters into Research Agreement with Institute for Systems Biology Janssen Research & Development Enters into Research Agreement with Skaggs School of Pharmacy and Pharmaceutical Sciences

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

Janssen Biotech Enters into Agreement with Eureka Therapeutics Intrexon Enters into Research Agreement with Janssen Pharma Cypralis Enters into Research Agreement with Janssen Pharma Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics Bioaster, Cancer Research Center of Lyon and Janssen-Cilag Enter into Agreement SynAging Extends Agreement with Actelion Pharma ViroGin Biotech Enters into With Johnson & Johnson Innovation and Janssen Biotech Nuevolution Enters into Discovery Agreement with Janssen Biotech enGene Enters into Agreement with Janssen Biotech OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech BlinkBio Enters into Discovery Agreement with Janssen Pharma UbiVac Enters into Agreement with Janssen Biotech Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College Nextera Enters into Research Agreement with Janssen Biotech Handok Enters into Agreement with Actelion Pharmaceuticals Actelion Forms Joint Venture with Max Planck Society Johnson & Johnson Enters into Agreement with University of the Witwatersrand Janssen Cilag Enters into Agreement with UniQuest Johnson & Johnson Innovation Enters into Research Agreement with Washington University Janssen Biotech Enters into Research Agreement with Emulate Johnson & Johnson Innovation Partners with Lead Discovery Center NeurOp Enters into Research Agreement with Janssen Pharma AC Immune Enters into Research Agreement with Janssen Pharma X-Chem Expands Agreement with Janssen Biotech Vectura Enters into Development and License Agreement with Janssen Biotech Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA- Targeted Therapeutics Sevion Therapeutics Enters into Discovery Agreement with CNA Development Atreca Enters into Research Agreement with Janssen Biotech Vaccinex Enters into Research Agreement with Janssen Research & Development Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation Johnson & Johnson Enters into Co-Development Agreement with University of Manchester

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland Alector Enters Into Research Agreement With Janssen Pharma University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech Nodality Enters Into Research Agreement With Johnson & Johnson Innovation Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications Evotec Enters Into Co-Development Agreement With Johnson & Johnson ZoBio Enters Into Drug Discovery Agreement With Actelion Pharma For Fragment Ligands AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Joslin Diabetes Center Enters Into R&D Agreement With Johnson & Johnson For Diabetes Management DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs ex scientia Enters into Agreement with Janssen Research & Development Mellitech Enters into Agreement with Janssen Pharma Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug Portola Pharma Enters into Agreement with Bayer and Janssen Pharma Araxes Pharma Enters Into Drug Discovery Agreement With Janssen Biotech For Cancer Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody Open Monoclonal Expands Agreement with CNA Development Beactica Enters Into Research Agreement With Janssen Research & Development Janssen-Cilag Enters Into Research Agreement With University of Melbourne Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

Artes Biotechnology Enters Into Co-Development Agreement With Crucell Selventa Enters Into Co-Development Agreement With Janssen Research & Development Johnson & Johnson Enters Into Co-Development Agreement With University of Queensland Dendright Enters Into Research Agreement With Janssen-Cilag FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech Licensing Agreements Janssen Pharma to Enter into Licensing Agreement with Arrowhead Pharma Immune Biosolutions Enters into Licensing Agreement with Janssen Biotech Macleods Pharma May Enter into Licensing Agreement with Johnson & Johnson Janssen Biotech Enters into Licensing Agreement with Nuevolution Janssen Biotech Enters into Licensing Agreement with Legend Biotech Janssen Biotech Enters into Licensing Agreement with Ionis Pharma Janssen Biotech Enters into Licensing Agreement with Zymeworks Provention Enters into Licensing Agreement with Janssen Pharma and Janssen Sciences Ireland Janssen Biotech Enters into Licensing Agreement with Protagonist Therapeutics Janssen Pharma Enters into Licensing Agreement with St Vincent’s Institute of Medical Research Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic Pulmatrix Enters into Licensing Agreement with RespiVert Janssen Biotech Enters into Licensing Agreement with Trianni Janssen Biotech Enters into Licensing Agreement with Ablexis Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma Janssen Pharma Enters into Licensing Agreement with University of Massachusetts CPDC Enters into Licensing Agreement with Janssen Biotech for Centyrin OCTIMET Oncology Enters into Licensing Agreement with Janssen Pharma BenevolentAI Enters into Licensing Agreement with Janssen Pharma Actelion Enters into Licensing Agreement with ReveraGen BioPharma TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference GlaxoSmithKline Enters into Licensing Agreement with Janssen Sciences Ireland Janssen Biotech Enters into Licensing Agreement with Ionis Pharma Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics Janssen Biotech Enters into Licensing Agreement with MacroGenics for MGD015

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

Janssen Biotech Enters into Licensing agreement with Tesaro ViaCyte Enters into Licensing Agreement with Janssen Biotech Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma Janssen Biotech Enters into Licensing Agreement with Alligator Bioscience for ADC-1013 Poseida Therapeutics Enters into Licensing Agreement with Janssen Biotech Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma Poseida Therapeutics Enters into Licensing Agreement with Janssen Novo Nordisk Enters into Licensing Agreement with Janssen Biotech GBC-Atrial Enters into Licensing Agreement with Actelion Pharma Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma Infirst Healthcare Enters into Licensing Agreement with McNeil Consumer Pharma Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma Applied Molecular Transport Enters into Licensing Agreement with Janssen Biotech Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech AC Immune Enters into Licensing Agreement with Janssen Pharma Janssen Expands Licensing Agreement with Gilead Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib Kura Oncology Amends Licensing Agreement with Janssen Pharma Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech Modern Biosciences Enters into Licensing Agreement with Janssen Biotech Transposagen BioPharma Enters into Licensing Agreement with Janssen Biotech BeneVir Biopharm Enters into Licensing Agreement with New York University AB-Biotics Enters into Licensing Agreement with Cilag Bavarian Nordic Enters into Licensing Agreement with Crucell Holland Aduro BioTech Enters into Licensing Agreement with Janssen Biotech Minerva Amends Licensing Agreement with Janssen Pharma for MIN-202 Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology Janssen R&D Ireland Extends Licensing Agreement With International Partnership For Microbicides Janssen Pharma Enters into Licensing Agreement with BiocerOX Orion Enters Into Licensing Agreement With Janssen Pharma CSL Enters Into Licensing Agreement With Janssen For CSL-362

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 XO1 Enters into Licensing Agreement with Cambridge Enterprise Amunix Expands Licensing Agreement With Janssen For XTEN Technology Amunix Expands Licensing Agreement With Janssen Biotech For Proprietary XTEN Technology GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists Phenex Pharma Enters Into Licensing Agreement With Janssen Biotech For Retinoid- Acid Receptor-Related Orphan Receptor Gamma t Program Shionogi Enters Into Licensing Agreement With Janssen Pharma Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs ImmuNext Enters Into Licensing Agreement With Janssen Biotech Genmab Enters into Licensing Agreement with Janssen Biotech for Daratumumab Depomed Enters Into Licensing Agreement With Janssen Pharma Genmab Enters into Licensing Agreement with Janssen Biotech for DuoBody Technology Genmab Expands Licensing Agreement With Janssen Biotech Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates Phylogica Enters Into Licensing Agreement With Janssen Biotech For Phylomer Technology Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics Janssen Biotech Exercises Option for Licensing Agreement with X-Chem Dishman Pharma Enters into Licensing Agreement with Janssen Pharma BRIM Biotechnology Enters into Licensing Agreement with Janssen Pharma ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs Amunix Exercises Option For Licensing Agreement With Janssen Biotech For XTEN Technology

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

Intravacc Enters into Licensing Agreement with Crucell Holland Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases BioLife Solutions Enters Into Licensing Agreement With Janssen Research & Development For CryoStor Janssen Pharma Enters Into Licensing Agreement With Pharmstandard For Bedaquiline, Anti-Tuberculosis Drug NewVac Enters Into Licensing Agreement With Janssen For Quisinostat Mucosis To Enter Into Licensing Agreement With Crucell For Mimopath Technology Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates Kuros Biosurgery Enters Into Licensing Agreement With Synthes Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug Equity Offering Bavarian Nordic Raises USD32.5 Million in Private Placement of Shares Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business Achillion Pharma to Raise Funds through Secondary Offering of Shares Alligator Bioscience Raises USD252.8 Million in IPO Tesaro Raises USD50 Million in Private Placement of Shares Achillion Pharma Raises USD225 Million in Private Placement of Shares Minerva Neurosciences Raises USD31 Million in Private Placement of Shares Kura Oncology Raises USD60 Million in Private Placement of Common Stock MacroGenics Raises USD75 Million in Private Placement of Common Stock Bavarian Nordic Raises USD43 Million in Private Placement of Shares Debt Offering PhaseBio Pharma to Raise USD8.1 Million in Second Tranche of Private Placement of Convertible Notes PhaseBio Pharma Raises USD14.7 Million in Private Placement of Convertible Notes Johnson & Johnson Plans to Raise Funds through Public Offering of Notes Johnson & Johnson Completes Public Offering Of Notes Due 2018 For US$600 Million Johnson & Johnson Completes Public Offering Of Notes Due 2016 For US$400 Million Johnson & Johnson Completes Public Offering Of Notes Due 2023 For US$550 Million Johnson & Johnson Completes Public Offering Of Notes Due 2033 For US$650 Million Johnson & Johnson Completes Public Offering Of Notes Due 2043 For US$500 Million Johnson & Johnson Completes Public Offering Of Notes Due 2016 For US$800 Million Asset Transactions Eusa Pharma to Acquire Sylvant from Janssen Sciences Ireland for USD115 Million Stada Arzneimittel Acquires Nizoral from Janssen Pharma

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

Kramer Labs Acquires Nizoral from Janssen Pharma Alliance Pharma Acquires Nizoral from Janssen Pharma for USD79.5 Million VIVUS Acquires Assets from Janssen Pharma for USD135 Million Helsinn Healthcare to Acquire Rights of Valchlor/Ledaga from Actelion Pharma Sinocare May Acquire Diabetes Care Business from Johnson & Johnson for up to USD4 Billion HRA Pharma Acquires Compeed from Cilag Trimb Healthcare Acquires OTC Products from Cilag and Janssen Pharma Church & Dwight Acquires Anusol and Rectinol Business from Johnson & Johnson for USD130 Million Piramal to Acquire Five Anesthesia and Pain Management Injectable Products from Janssen Pharma Strides Arcolab to Acquire Seven Brands from Johnson & Johnson Air Liquide Acquires Healthcare Antisepsis Solutions from Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion Vivus Acquires Related Patents from Janssen Pharma PaxVax Acquires Vivotif from Crucell Reckitt Benckiser To Acquire K-Y Lubricants Brand From McNEIL-PPC Bertin Pharma Acquires R&D Facility from Johnson & Johnson Sante Beaute France Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson Completes Acquisition Of Rolaids From McNEIL-PPC Recordati Acquires Dentosan Line Of Oral Care Products From Cilag Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Recordati Acquires Six Over The Counter Products From Cilag And McNeil Forest Labs Acquires Patents And Intellectual Property For Bystolic From Janssen Pharma For US$357 Million Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica Acquisition Janssen Biotech Acquires 76% stake in BeneVir Biopharm Johnson & Johnson Acquires Actelion for USD30 Billion Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas Ethicon Acquires Torax Medical Johnson & Johnson Acquires Abbott Medical Optics from for USD4.32 Billion Johnson & Johnson Consumer Acquires NeoStrata DePuy Orthopaedics Acquires BioMedical Enterprises Johnson & Johnson Sells its 5.1% Interest in Galapagos for USD95.7 Million

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

Johnson and Johnson May Sell Noramco Johnson & Johnson Acquires Novira Therapeutics Biosense Webster Acquires Coherex Medical Actelion Plans to Acquire ZS Pharma Actelion Rejects Acquisition Offer from Shire Janssen Pharma Acquires XO1 Valneva Acquires Crucell Sweden for USD54 Million Tetraphase Pharma May Sell Itself Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion Cilag Acquires Covagen Novartis Acquires CoStim Pharma Actelion Completes Acquisition Of Ceptaris Therapeutics For US$250 Million Johnson & Johnson Completes Acquisition Of Aragon Pharma For USD1 Billion Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics Ipsen Acquires Syntaxin, Life Sciences Company, For USD206 Million Johnson & Johnson Completes Acquisition Of Shanghai Elsker For Mother & Baby Abbott, Johnson & Johnson And Mull Individual Acquisition Of Bausch & Lomb Janssen Biotech To Acquire Vascular Pharma, Diabetes Drug Developer Janssen-Cilag Acquires CorImmun Johnson & Johnson - Key Competitors Johnson & Johnson - Key Employees Johnson & Johnson - Locations And Subsidiaries Head Office Other Locations & Subsidiaries Recent Developments Strategy And Business Planning Oct 03, 2018: J&J concludes sale of LifeScan to Platinum Equity for $2.1bn Financial Announcements Jul 17, 2018: Johnson & Johnson Reports 2018 Second-Quarter Results Apr 17, 2018: Johnson & Johnson Reports 2018 First-Quarter Results Jan 23, 2018: Johnson & Johnson Reports 2017 Fourth-Quarter Results Oct 17, 2017: Johnson & Johnson Reports 2017 Third-Quarter Results Jul 18, 2017: Johnson & Johnson Reports 2017 Second-Quarter Results Apr 19, 2017: Johnson & Johnson reports Q1 2017 results Apr 18, 2017: Johnson & Johnson Reports 2017 First-Quarter Results Jan 24, 2017: Johnson & Johnson Reports 2016 Fourth-Quarter Results Corporate Communications Jun 22, 2018: Johnson & Johnson Announces Retirement of Group Worldwide Chairman, Sandra E. Peterson

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

Jun 22, 2018: Johnson & Johnson Appoints Senior Leaders to Executive Committee Mar 20, 2018: Dominic J. Caruso to Retire as Chief Financial Officer of Johnson & Johnson May 15, 2017: Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson Legal and Regulatory Apr 03, 2018: JNJ DEADLINE NOTICE: Rosen Law Firm Reminds Johnson & Johnson Investors of Important April 9, 2018 Deadline in Class Action - JNJ Sep 19, 2017: GHJP Closes Two-Year FOIA Case Against Drug Manufacturer May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic Jan 05, 2017: Missouri Court Denies J&J Request to Delay Talc-Related Cancer Trials Government and Public Interest Jun 05, 2018: Johnson & Johnson Announces Progress Toward Health for Humanity Goals Dec 05, 2017: Bioethics International Releases the 'Good Pharma Scorecard' in BMJ Open, Ranking the Top 20 Largest Pharmaceutical Companies on Clinical Trial Transparency Nov 30, 2017: New HIV Prevention Trials Hold Promise for New Prevention Options for Women Product News 12/11/2017: Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers 09/29/2017: Johnson & Johnson Advances Investigational Ebola Prime-boost Vaccine Regimen with New Partnership 08/02/2017: FDA Advisory Committee Does Not Recommend Approval Of Sirukumab For The Treatment Of Moderately To Severely Active Rheumatoid Arthritis 07/18/2018: Update on Janssens BACE inhibitor program regarding the dominantly inherited al

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

List Of Tables

LIST OF TABLES

Johnson & Johnson, Pharmaceuticals & Healthcare, Key Facts, 2017 Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 Johnson & Johnson, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 Johnson & Johnson, Deals By Therapy Area, 2012 to YTD 2018 Johnson & Johnson, Medical Devices Deals, 2012 to YTD 2018 Johnson & Johnson, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 Janssen Pharma Acquires CERC-501 from Cerecor Cilag Acquires Rights to Rhinocort Aqua Outside the US from Astrazeneca Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing PhaseBio Pharma Raises USD34 Million in Series D Venture Financing ApoGen Biotech Raises Additional USD4 Million in Series A Financing Magnolia Neurosciences Raises USD31 Million in Series A Venture Financing Evolve BioSystems Raises USD40 Million in Series C Financing Syndesi Therapeutics Raises USD21 Million in Series A Financing On Target Labs Raises USD40 Million in Series B Financing BeneVir Biopharm Raises USD2 Million in Venture Financing Fusion Pharma Raises Additional USD17 Million in Series A Financing XW Labs Raises USD17.5 Million in Series B Financing Rodeo Therapeutics Raises USD5.9 Million in Series A Financing E-scape Bio Raises Additional USD8 Million in Series A Financing DayTwo Secures USD12 Million in Series A Funding DayTwo Raises USD12 Million in Series A Financing Aragon Pharmaceuticals Raises USD22 Million in Series B Rou

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile +44 20 8123 2220 [email protected]

I would like to order

Product name: Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Product link: https://marketpublishers.com/r/JCB7887443BEN.html Price: US$ 250.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: [email protected]

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/JCB7887443BEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature ______

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Powered by TCPDF (www.tcpdf.org)